Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | Director | June 10, 2026 | June 10, 2026 |
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director | May 01, 2019 | June 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FENNEC PHARMACEUTICALS INC.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.70 · Expires 2036-06-10 | Direct | 200,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 20,000 · Balance 200,000 F1: On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2: The option is 100% vested on date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.
F2: The option is 100% vested on date of grant.
TENAX THERAPEUTICS, INC.
Report date May 01, 2019 · Filed June 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2030-05-01 | Direct | 500 |
Reported balance
After 2020-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-01 · Grant · Acquired 500 · Balance 500 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2029-05-01 | Direct | 500 |
Reported balance
After 2019-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-01 · Grant · Acquired 500 · Balance 500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 10, 2026 21:24 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 20,000 | $8.70 Strike: $8.70 | $174,000.00 |
DisclosureSEC source: 0001185945-26-000004 · form4-06102026_090645.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common shares · 20,000 shares Expires 2036-06-10 F1 · security: On June 10, 2026, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Option · Derivative | 14,344 | $2.44 Strike: $2.44 | $34,999.36 |
DisclosureSEC source: 0001185945-26-000002 · form4-05122026_040501.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,189 Underlying: Common shares · 14,344 shares Expires 2026-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on May 19, 2025. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 8,346 | $7.04 | $58,755.84 |
DisclosureSEC source: 0001185945-26-000002 · form4-05122026_040501.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,077 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 14,344 | $2.44 | $34,999.36 |
DisclosureSEC source: 0001185945-26-000002 · form4-05122026_040501.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on May 19, 2025. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 4,062 | $1.23 Strike: $1.23 | $4,996.26 |
DisclosureSEC source: 0001185945-25-000005 · form4-10142025_041001.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,344 Underlying: Options · 4,062 shares Expires 2025-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on May 19, 2025. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 1,775 | $9.24 | $16,401.00 |
DisclosureSEC source: 0001185945-25-000005 · form4-10142025_041001.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,079 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| October 10, 2025 Filed Oct 14, 2025 20:10 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 4,062 | $1.23 | $4,996.26 |
DisclosureSEC source: 0001185945-25-000005 · form4-10142025_041001.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on May 19, 2025. Read SEC document |
| July 07, 2025 Filed Jul 7, 2025 21:31 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 2,127 | $2.35 Strike: $2.35 | $4,998.45 |
DisclosureSEC source: 0001415889-25-019433 · form4-07072025_090710.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,406 Underlying: Options · 2,127 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| July 07, 2025 Filed Jul 7, 2025 21:31 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 1,119 | $8.71 | $9,746.49 |
DisclosureSEC source: 0001415889-25-019433 · form4-07072025_090710.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,792 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| July 07, 2025 Filed Jul 7, 2025 21:31 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 2,127 | $2.35 | $4,998.45 |
DisclosureSEC source: 0001415889-25-019433 · form4-07072025_090710.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 20,000 | $7.88 Strike: $7.88 | $157,600.00 |
DisclosureSEC source: 0001415889-25-015587 · form4-06042025_040604.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,533 Underlying: Common shares · 20,000 shares Expires 2035-06-03 F1 · security: On June 3, 2025, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| April 11, 2025 Filed Apr 11, 2025 20:31 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 2,173 | $2.30 Strike: $2.30 | $4,997.90 |
DisclosureSEC source: 0001415889-25-010574 · form4-04112025_080457.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,533 Underlying: Options · 2,173 shares Expires 2025-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| April 11, 2025 Filed Apr 11, 2025 20:31 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 1,409 | $4.95 | $6,974.55 |
DisclosureSEC source: 0001415889-25-010574 · form4-04112025_080457.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,784 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| April 11, 2025 Filed Apr 11, 2025 20:31 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 2,173 | $2.30 | $4,997.90 |
DisclosureSEC source: 0001415889-25-010574 · form4-04112025_080457.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: . Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| February 14, 2025 Filed Feb 14, 2025 23:13 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 1,992 | $2.51 Strike: $2.51 | $4,999.92 |
DisclosureSEC source: 0001415889-25-004249 · form4-02142025_110245.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,706 Underlying: Options · 1,992 shares Expires 2025-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| February 14, 2025 Filed Feb 14, 2025 23:13 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 1,186 | $6.82 | $8,088.52 |
DisclosureSEC source: 0001415889-25-004249 · form4-02142025_110245.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,020 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| February 14, 2025 Filed Feb 14, 2025 23:13 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 1,992 | $2.51 | $4,999.92 |
DisclosureSEC source: 0001415889-25-004249 · form4-02142025_110245.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:07 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 10,000 | $2.69 Strike: $2.69 | $26,900.00 |
DisclosureSEC source: 0001415889-24-028018 · form4-12032024_121231.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,698 Underlying: Options · 10,000 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:07 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 6,409 | $6.14 | $39,351.26 |
DisclosureSEC source: 0001415889-24-028018 · form4-12032024_121231.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,214 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:07 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 10,000 | $2.69 | $26,900.00 |
DisclosureSEC source: 0001415889-24-028018 · form4-12032024_121231.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:14 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 1,960 | $2.55 Strike: $2.55 | $4,998.00 |
DisclosureSEC source: 0001415889-24-024986 · form4-10102024_091037.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,698 Underlying: Options · 1,960 shares Expires 2024-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:14 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 1,406 | $4.53 | $6,369.18 |
DisclosureSEC source: 0001415889-24-024986 · form4-10102024_091037.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,623 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 21:14 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 1,960 | $2.55 | $4,998.00 |
DisclosureSEC source: 0001415889-24-024986 · form4-10102024_091037.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 23:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 20,000 | $5.58 Strike: $5.58 | $111,600.00 |
DisclosureSEC source: 0001415889-24-021638 · form4-08192024_110803.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,658 Underlying: Common shares · 20,000 shares Expires 2034-08-15 F1 · security: On August 15, 2024, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested of date of grant. Read SEC document |
| July 05, 2024 Filed Jul 8, 2024 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 1,792 | $2.79 Strike: $2.79 | $4,999.68 |
DisclosureSEC source: 0001415889-24-019332 · form4-07082024_040704.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,802 Underlying: Options · 1,792 shares Expires 2024-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 program adopted August 17, 2023. Read SEC document |
| July 05, 2024 Filed Jul 8, 2024 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 1,173 | $6.03 | $7,073.19 |
DisclosureSEC source: 0001415889-24-019332 · form4-07082024_040704.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,457 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| July 05, 2024 Filed Jul 8, 2024 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 1,792 | $2.79 | $4,999.68 |
DisclosureSEC source: 0001415889-24-019332 · form4-07082024_040704.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| April 15, 2024 Filed Apr 15, 2024 22:15 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 1,389 | $3.60 Strike: $3.60 | $5,000.40 |
DisclosureSEC source: 0001415889-24-010817 · form4-04152024_100414.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,594 Underlying: Options · 1,389 shares Expires 2024-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 program adopted August 17, 2023. Read SEC document |
| April 15, 2024 Filed Apr 15, 2024 22:15 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 1,389 | $10.45 | $14,515.05 |
DisclosureSEC source: 0001415889-24-010817 · form4-04152024_100414.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| April 15, 2024 Filed Apr 15, 2024 22:15 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 800 | $10.45 | $8,360.00 |
DisclosureSEC source: 0001415889-24-010817 · form4-04152024_100414.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,449 F1 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| March 26, 2024 Filed Mar 27, 2024 20:24 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 4,329 | $2.31 Strike: $2.31 | $9,999.99 |
DisclosureSEC source: 0001415889-24-009205 · form4-03272024_080358.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,983 Underlying: Options · 4,239 shares Expires 2024-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| March 26, 2024 Filed Mar 27, 2024 20:24 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 4,329 | $2.31 | $9,999.99 |
DisclosureSEC source: 0001415889-24-009205 · form4-03272024_080358.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option pusuant to a 10b5-1 plan adopted on August 17, 2023. Read SEC document |
| March 26, 2024 Filed Mar 27, 2024 20:24 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 2,114 | $10.97 | $23,190.58 |
DisclosureSEC source: 0001415889-24-009205 · form4-03272024_080358.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,920 F1 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 21:02 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 3,144 | $1.59 Strike: $1.59 | $4,998.96 |
DisclosureSEC source: 0001104659-23-130042 · tm2333865-1_4seq1.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,168 Underlying: Options · 3,144 shares Expires 2024-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option contract with strike price of $1.59 and an expiration date of January 24, 2024. F3 · shares: Represents options granted on January 24, 2014, with a strike price of $1.59 and expiration date of January 24, 2024. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 21:02 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 3,144 | $1.59 | $4,998.96 |
DisclosureSEC source: 0001104659-23-130042 · tm2333865-1_4seq1.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option contract with strike price of $1.59 and an expiration date of January 24, 2024. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 21:02 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 1,390 | $10.90 | $15,151.00 |
DisclosureSEC source: 0001104659-23-130042 · tm2333865-1_4seq1.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,788 F1 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 02:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 269 | $8.25 | $2,219.25 |
DisclosureSEC source: 0001415889-23-015314 · form4-11202023_091101.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,034 F1 · security: Shares sold pursuant to a 10b5-1 agreement dated March 18, 2022. Sharee sold at a price of $8.25. Read SEC document |
| August 18, 2023 Filed Aug 18, 2023 21:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 673 | $7.85 | $5,283.05 |
DisclosureSEC source: 0001415889-23-012411 · form4-08182023_050802.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,303 F1 · security: Shares originally acquired through the exercise of an option with strike price of $0.45, and an original expiration date of August 17, 2022. Read SEC document |
| July 24, 2023 Filed Jul 24, 2023 21:04 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 16,666 | $0.72 Strike: $0.72 | $11,999.52 |
DisclosureSEC source: 0001415889-23-011416 · form4-07242023_090724.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,312 Underlying: Options · 16,666 shares Expires 2023-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options granted on August 23, 2013, with a strike price of $0.72 and an expiration date of August 23, 2023. Read SEC document |
| July 24, 2023 Filed Jul 24, 2023 21:04 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 6,796 | $8.17 | $55,523.32 |
DisclosureSEC source: 0001415889-23-011416 · form4-07242023_090724.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,976 F2 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| July 24, 2023 Filed Jul 24, 2023 21:04 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 16,666 | $0.72 | $11,999.52 |
DisclosureSEC source: 0001415889-23-011416 · form4-07242023_090724.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option contract with strike price of $0.72 and an expiration date of August 23, 2023. Read SEC document |
| July 06, 2023 Filed Jul 6, 2023 21:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares · Derivative | 5,208 | $0.96 Strike: $0.96 | $4,999.68 |
DisclosureSEC source: 0001415889-23-010905 · form4-07062023_090736.xml · derivative · entry 3 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,978 Underlying: Options · 5,208 shares Expires 2023-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options granted on August 6, 2013, with a strike price of $0.96 and expiration date of August 6, 2023. Read SEC document |
| July 06, 2023 Filed Jul 6, 2023 21:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 5,280 | $0.96 | $5,068.80 |
DisclosureSEC source: 0001415889-23-010905 · form4-07062023_090736.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Shares acquired through the exercise of an option contract with strike price of $0.96 and an expiration date of August 6, 2023. Read SEC document |
| July 06, 2023 Filed Jul 6, 2023 21:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 2,207 | $8.47 | $18,693.29 |
DisclosureSEC source: 0001415889-23-010905 · form4-07062023_090736.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,826 F1 · security: Shares sold to satisfy tax obligation on option exercise. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 15:42 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001415889-23-009702 · form4-06132023_030600.xml · derivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,186 Underlying: Common shares · 20,000 shares Expires 2033-06-12 F1 · security: On June 12, 2023, Chris Rallis was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested of date of grant. Read SEC document |
| May 19, 2023 Filed May 19, 2023 20:41 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 925 | $7.36 | $6,808.00 |
DisclosureSEC source: 0001415889-23-008417 · form4-05192023_080541.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,033 F2 · shares: Sale of common shares sold in accordance with 10b5-1 plan. Commom shares resulted from exercise of option grant with grant date of 5/17/2012. Read SEC document |
| May 19, 2023 Filed May 19, 2023 20:41 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 833 | $7.36 | $6,130.88 |
DisclosureSEC source: 0001415889-23-008417 · form4-05192023_080541.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,958 F1 · shares: Sale of common shares sold in accordance with 10b5-1 plan. Commom shares resulted from exercise of option grant with grant date of 4/4/2012. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 01:25 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon Shares | 986 | $8.34 | $8,223.24 |
DisclosureSEC source: 0001415889-23-006577 · form4-04182023_010400.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,791 F2 · security: Represents shares automatically sold pursuant to a 10b5-1 plan to an irrevocable sell to cover election to satisfy tax withholding obligation in connectionwith the exercise of 1,700 shares from a May 2013 grant. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 01:25 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 1,700 | $2.94 | $4,998.00 |
DisclosureSEC source: 0001415889-23-006577 · form4-04182023_010400.xml · nonDerivative · entry 1 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents options granted May 17, 2013, with a $2.94 strike price aand expiration of May 17, 2023. Read SEC document |
| March 03, 2023 Filed Mar 3, 2023 22:35 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Tax withholdingCommon Shares | 2,177 | $9.09 | $19,788.93 |
DisclosureSEC source: 0001415889-23-004182 · form4-03032023_100359.xml · nonDerivative · entry 2 RALLIS CHRIS A · CIK 0001185945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,077 F2 · security: Represents shares automatically sold pursuant to a 10b5-1 plan to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the exercise of 4,166 shares from an April 3, 2013 grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.